Medically reviewed by Alex Yampolsky, PharmD Pristiq (desvenlafaxine) and Effexor (venlafaxine) are prescription medications ...

For many women who experience hot flashes, the new drug Veozah has been a life-changer. And a heightened warning last month, doesn’t seem to be dampening that enthusiasm.

Menopause is a huge mental, emotional and physical change. Here's what you need to know about this stage of life, including ...

Thursday, Bayer shared top-line data from a phase 3 trial that tested elinzanetant in women on adjuvant endocrine therapy for breast cancer. The anticancer therapy can cause hot flashes, known ...

[34] In December 2006, the FDA approved the marketing of Elestrin (estradiol gel) in the USA to treat moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause. Two doses of ...

The Andhra Pradesh cabinet approves two engineering projects worth Rs 2,723 crore for Amaravati, including a green ammonia manufacturing facility and South India's first integrated energy project.

The Food and Drug Administration (FDA) gave the green light to the the first-ever medication for obstructive sleep apnea (OSA). The newly approved drug, Zepbound (tirzepatide), targets adults with ...

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in the U.S., the agency has cleared an under-the-skin version of the ...

Ryoncil, the first mesenchymal stromal cell therapy, showed a 70% overall response rate in pediatric steroid-refractory acute GVHD, with a median DOR of 54 days. The FDA approved several drugs in ...

Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed ...

The US Food and Drug Administration has placed its most serious alert — a so-called black-box warning — on a drug used to relieve menopausal hot flashes. The menopause drug Veozah hit the ...

The Food and Drug Administration (FDA) on Dec. 20 approved the obesity medication Zepbound (tirzepatide) as the first pharmaceutical treatment for moderate-to-severe obstructive sleep apnea (OSA) in ...